key: cord-0739038-sk76nw2h
authors: Verburgh, Myrthe L; Boyd, Anders; Wit, Ferdinand W N M; Schim van der Loeff, Maarten F; van der Valk, Marc; Bakker, Margreet; Kootstra, Neeltje A; van der Hoek, Lia; Reiss, Peter
title: Similar risk of SARS-CoV-2 infection and similar nucleocapsid antibody levels in people with well-controlled HIV and a comparable cohort of people without HIV
date: 2021-12-20
journal: J Infect Dis
DOI: 10.1093/infdis/jiab616
sha: 01b1bd1462e6ef3a3b650a942f634a509cdabef6
doc_id: 739038
cord_uid: sk76nw2h

BACKGROUND: Within the ongoing AGEhIV Cohort Study in Amsterdam, we prospectively compared the incidence of and risk factors for SARS-CoV-2 infection between HIV-positive and -negative participants. Moreover, we compared SARS-CoV-2 nucleocapsid antibody levels between participants with incident infection from both groups. METHODS: Starting in September 2020, consenting HIV-positive and HIV-negative participants were assessed 6-monthly for incident SARS-CoV-2 infection, using combined IgA/IgM/IgG SARS-CoV-2 nucleocapsid antibody assay. Cumulative incidence of SARS-CoV-2 infection and associated risk factors were assessed from February 27, 2020 through April 30, 2021 using complementary log-log regression. In those with incident SARS-CoV-2 infection, N-antibody levels were compared between groups using linear regression. RESULTS: 241 HIV-positive (99.2% virally suppressed) and 326 HIV-negative AGE(h)IV participants were included in this study. Cumulative SARS-CoV-2 incidence by April 2021 was 13.4% and 11.6% in HIV-positive and HIV-negative participants, respectively (p=0.61). Younger age and African origin were independently associated with incident infection. In those with incident infection, only self-reported fever, but not HIV status, was associated with higher N-antibody levels. CONCLUSIONS: HIV-positive individuals with suppressed viremia and adequate CD4 cell counts were had similar risk of SARS-CoV-2 acquisition, and had similar SARS-CoV-2 N-antibody levels following infection compared to a comparable cohort of HIV-negative people.

(PWH), studies investigating the acquisition of SARS-CoV-2 infection and COVID-19 severity conducted in different parts of the world have reported contrasting findings. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Most studies report a similar [8, 10, 11, 14, 15] or even lower [9, 13] incidence of PCR-confirmed SARS-CoV-2 infection among HIV-positive compared to HIV-negative groups. However, some studies have compared incidence in PWH to data from the general population [8, 9, 13] , whereas others have compared it to individuals without HIV using population-based surveillance registers [10, 11, 14] . Only one study has compared SARS-CoV-2 incidence in PWH to a group of age-, race-, sexand site-matched HIV-negative people [15] .

In the general population, the majority of people with symptomatic SARS-CoV-2 infection, with or without confirmation by PCR, develop detectable antibodies against the nucleocapsid (N), spike (S) and receptor binding domain (RBD) protein. [19] [20] [21] N-antibodies are detectable in more than 91% of individuals following a symptomatic SARS-CoV-2 infection. [22, 23] Vaccination with the currently European Medicines Agency-approved vaccines all trigger an immune response to the SARS-CoV-2 S-protein but do not elicit N-antibodies. [24] [25] [26] [27] SARS-CoV-2 N-antibodies are thus an appropriate marker to detect past SARS-CoV-2 infection, including infection acquired despite partial or complete vaccination. Several studies found that SARS-CoV-2 N-antibodies remained detectable for at least 8 months after infection, although levels may decline over time. [28, 29] A c c e p t e d M a n u s c r i p t 7 SARS-CoV-2 S-and N-antibody titres each correlate with disease severity, titres being higher in patients with moderate to severe COVID-19 than in those with asymptomatic or mild symptomatic infection. [21, [29] [30] [31] Moreover, one general population study reported older age and higher BMI to also be associated with higher N-antibody titres. [32] Few studies have addressed the potential impact of HIV on the antibody response to SARS-CoV-2 infection. One small cross-sectional study reported no significant difference in SARS-CoV-2 N-antibody titres between 47 PWH and 35 HIV-negative health care workers. [33] Another small study in 28 PWH found no difference in SARS-CoV-2 IgG N-titres between PWH with CD4 cell counts ≥500 or <500 cells/mm 3 . [8] No study has prospectively compared the acquisition of symptomatic or asymptomatic SARS-CoV-2 and the antibody response to infection between people with well-controlled HIV and comparable HIV-negative individuals. We therefore conducted a study of this design nested within our ongoing AGEhIV cohort study in Amsterdam.

The AGEhIV Cohort Study is a prospective observational cohort study assessing the prevalence Amsterdam, resulting in a control group with highly similar socio-demographic and behavioural characteristics. At baseline and every 2 years thereafter, patients undergo standardized screening for age-related comorbidities, and collection of blood, urine and stool for cryopreservation. Details have been described previously. [34] A c c e p t e d M a n u s c r i p t 8 In August 2020, following the first SARS-CoV-2 epidemic wave in the Netherlands, all AGEhIV Cohort participants in active follow-up and residing in the Netherlands were asked to participate in a COVID-19 substudy, which includes five planned, six-monthly study visits between September 2020 and October 2022. During each visit, blood is obtained to assess SARS-CoV-2 humoral and cellular immune responses and participants complete a standardized study questionnaire.

For the current analysis, data from the first and second six-monthly study visits (September-October 2020 and March-April 2021) were used. These data capture approximately up to 14 months of possible exposure to SARS-CoV-2 in the Netherlands: from February 27, 2020 (the date at which the first case of COVID-19 was identified in the Netherlands) until April 30, 2021 (end of second COVID-19 substudy visit).

Written informed consent was obtained from all participants. The study was approved by the ethics committee of the Amsterdam UMC, location AMC and is registered at www.clinicaltrials.gov (NCT01466582).

Date of birth, sex at birth and ethnic origin obtained at time of enrolment into the AGEhIV Cohort Study were used for all participants. Other baseline characteristics were obtained from the last available parent cohort study visit prior to February 27, 2020, and included data on number of prevalent co-morbidities, lifestyle (i.e., smoking, alcohol use, recreational drug use, other A c c e p t e d M a n u s c r i p t 9 BMI was categorized as underweight (<18.5 kg/m 2 ), normal weight (18.5-24.9), overweight (25.0-29.9) or obese (≥30.0). Undetectable HIV-1 plasma viral load was defined as <50 copies/mL, while viral blips up to 200 copies/mL were also considered as undetectable.

At each substudy visit, participants were asked to complete a standardized questionnaire Table 1 ). Reasons for declining participation did not differ between HIV-positive and -negative participants (Supplementary Table 2 ).

The characteristics of included participants are shown in Table 1 . The majority were Caucasian males (83.4%) and the median age was 60. were fatigue, cough, rhinorrhoea, muscle ache, headache and fever. There was no significant difference between both groups, except for 'confusion', which was reported more often by HIVpositive participants.

Only two participants, both HIV-negative, reported that they had been admitted for >1 day to a general hospital ward with COVID-19 for treatment with supplemental oxygen.

HIV status was not independently associated with incidence of SARS-CoV-2 infection in both the univariable (Supplementary Table 3 ) and multivariable analysis (Table 3 ). In the univariable analysis, the association with self-reported compliance to social distancing did not reach statistical significance. In the multivariable analysis, incident SARS-CoV-2 infection was significantly associated with younger age and being of African origin, with none of these risk factors showing a statistically significant interaction with HIV status. Table 4 ) and multivariable analysis (Table 4 ). Having experienced fever in the six months prior to the positive SARS-CoV-2 N-antibody test was the only variable significantly associated with a higher N-antibody level in multivariable analysis.

A c c e p t e d M a n u s c r i p t

During 14 months of possible SARS-CoV-2 exposure, we found no significant difference in the cumulative incidence of infection between HIV-negative participants in our study and those who were HIV-positive and -with few exceptions -were on cART with suppressed viremia and a reasonably high CD4 cell count. Having HIV also did not significantly impact the SARS-CoV-2 Nantibody level, as measured by INgezim® COVID-19 double recognition assay. Only two of our participants, both HIV-negative, had been admitted to the hospital for COVID-19, with neither having progressed to severe disease or death.

In our cohort, the cumulative incidence on October 31, 2020 and April 30, 2021 was 6.2% and 12.3%, respectively. This is similar to the SARS-CoV-2 seroprevalence for those 50 to 70 years old in the general Dutch population, which ranged between 4-6% and 10-15% in September among PWH compared to HIV-negative people. [38] Of note, participants were only matched for age and date of sampling; the two groups were not comparable with regards to sex, ethnic origin and prevalence of comorbidities, which likely affects the observed difference in seroprevalence between the groups. In our study, participants in both groups were highly comparable which might explain why we found no difference between the groups.

We found that living with HIV was not independently associated with an increased risk of SARS-CoV-2 infection. We did not find an association between incident SARS-CoV-2 infection and HIVspecific parameters. Of note, almost all HIV-positive participants in our study were virologically suppressed (99.2%), with almost 80% having ≥500 CD4 cells/mm 3 and virtually none had a clinically relevant degree of immunodeficiency. This limits our ability to assess the associations between HIV viral load, CD4 count and acquisition of SARS-CoV-2. However, other studies found no association between HIV viral load or current CD4 cell count and SARS-CoV-2 seropositivity. [38, 39] Moreover, most PCR-based prevalence studies also found no association between HIV-specific factors and SARS-CoV-2 infection [11, 13, 15, 16] . One study from Wuhan suggested a higher risk of SARS-CoV-2 infection in PWH who reported or were inferred to have had interrupted access to cART during the lockdown in the early stage of the epidemic [8] .

Younger age and being of African origin were each associated with an increased risk of SARS-CoV-2 infection in our analysis, without a significant interaction between these factors and HIV status. These findings corroborate the higher seroprevalence of SARS-CoV-2 in younger adults observed in other studies [38, 40, 41] , and are similar to observations in the general Dutch population [36] . A study among six ethnic groups living in Amsterdam likewise showed SARS-CoV-2 seroprevalence to be significantly higher in individuals of Ghanaian origin, compared to those of Dutch origin. [42] This increased risk in individuals of African origin might be associated with socio-economic factors, including lower income, being dependent of public A c c e p t e d M a n u s c r i p t 16 transport or working in a contact-based profession. Unfortunately, data on such factors were not available for our study.

In participants with an incident SARS-CoV-2 infection, N-antibody levels were not significantly different between HIV-positive and -negative participants, similar to what was reported by another study in which HIV-positive participants (with a median age of 52 years) all had undetectable viral load. [33] Moreover, in that study antibody titres were similar in HIV-positive participants with CD4 cell counts ≥500 cells/mm 3 compared to those with <500 cells/mm 3 A c c e p t e d M a n u s c r i p t 31 M a n u s c r i p t 32 

Risk factors for SARS-CoV-2 among patients in the

Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study

SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study

Assessing risk factors for SARS-CoV-2 infection in patients presenting with symptoms in Shanghai, China: a multicentre, observational cohort study

Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study

Characteristics and outcomes of COVID-19 in patients with HIV: a multicentre research network study

Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa

Epidemiological, virological and serological features of COVID-19 cases in people living with HIV in Wuhan City: A population-based cohort study

Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study

COVID-19 infection among people with HIV in New York City: A population-level analysis of linked surveillance data

SARS-CoV-2 percent positivity and risk factors among people with HIV at an urban academic medical center

COVID-19 Disease Severity among People with HIV Infection or Solid Organ Transplant in the United States: A Nationally-representative, Multicenter

Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study

COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State

COVID-19 in the Largest US HIV Cohort. AIDS 2020: 23rd International AIDS Conference Virtual

Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study

Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data

The interplay between HIV and COVID-19: summary of the data and responses to date

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

The first 12 months of COVID-19: a timeline of immunological insights

Persistence of antibodies to SARS-CoV-2 in relation to symptoms in a nationwide prospective study

Humoral Immune Response to SARS-CoV-2 in Iceland

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

Immunological memory to SARS-CoV-2 assessed for up to eight months after infection. bioRxiv, preprint: not peer reviewed

Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study

Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19

SARS-CoV-2 Antibody Responses Are Correlated to Disease Severity in COVID-19 Convalescent Individuals

SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo'

Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV

Cross-sectional comparison of the prevalence of ageassociated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study

Two serological approaches for detection of antibodies to SARS-CoV-2 in different scenarios: a screening tool and a point-of-care test

Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis

SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study

Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort

Estimated SARS-CoV-2 Seroprevalence in the US as of

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

Differences in SARS-CoV-2 infections during the first and second wave of SARS-CoV-2 between six ethnic groups in Amsterdam, the Netherlands: a population-based longitudinal serological study

Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses

Values represent adjusted hazard ratios (aHR) with 95% confidence interval. HR are adjusted for HIV status, age, ethnic origin and BMI. b. Number and percentage of participants with incident infection per total amount of participants for each variable category. c. At moment of SARS-CoV-2 N-antibody test

A c c e p t e d